Nuvation Bio Inc. — FY2023 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023. This is an annual report; it does not provide standalone fourth-quarter results. Nuvation Bio is a clinical-stage oncology biopharmaceutical company and has generated no product or collaboration revenue.
Financial performance and liquidity
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | No product or collaboration revenue | No product or collaboration revenue |
| Research and development expense | $71.3 million | $87.8 million |
| General and administrative expense | $28.5 million | $31.9 million |
| Total operating expenses / operating loss | $99.8 million | $119.7 million |
| Net loss | $75.8 million | $104.2 million |
| Net loss per share, basic and diluted | $0.35 | $0.48 |
| Cash used in operating activities | $68.0 million | $96.1 million |
At December 31, 2023, cash, cash equivalents and marketable securities totaled $611.2 million, compared with $661.0 million a year earlier. The balance comprised $42.6 million of cash and cash equivalents and $568.6 million of marketable securities. Management said these resources were expected to fund operations for at least 12 months after the financial statements were issued. The company reported $16.4 million of total liabilities, including operating lease liabilities and warrant liabilities; the filing does not report conventional borrowings. Profit margins are not meaningful because the company has no revenue. No off-balance-sheet financing arrangements were reported.
Changes versus 2022
- Net loss narrowed by $28.4 million, while operating expenses fell by $19.9 million.
- R&D expense declined $16.5 million, primarily because of lower third-party research and manufacturing costs following termination of the NUV-422 program, and a $2.4 million reduction in personnel costs following headcount reductions.
- G&A expense declined $3.4 million, mainly from lower insurance, legal, recruiting and other professional costs, partly offset by increased personnel-related costs.
- Other income, net, rose to $24.0 million from $15.5 million, primarily reflecting higher interest income ($24.6 million versus $7.4 million); the noncash warrant fair-value gain was smaller than in 2022.
- Operating cash use decreased by $28.1 million. Cash and cash equivalents fell by $58.5 million during 2023; investing cash flow largely reflected purchases and sales of marketable securities.
Pipeline, outlook and material risks
- NUV-868: The most advanced candidate, an oral BD2-selective BET inhibitor. The Phase 1 monotherapy study was completed and the maximum tolerated dose determined; Phase 1b combination studies with olaparib and enzalutamide were ongoing. Management planned a Phase 2 study after determining the recommended Phase 2 dose. The filing describes clinical development as early-stage and does not establish efficacy.
- NUV-1511: The first candidate from the drug-drug conjugate (DDC) platform. The FDA cleared its IND in January 2024, after year-end. Management intended to start a Phase 1/2 study in the first half of 2024 in patients with advanced solid tumors.
- The DDC platform and its potential safety, efficacy and manufacturing advantages remain unproven clinically. Nuvation relies on third parties for research, trials and manufacturing, with single-source suppliers used to date for investigational-product materials.
- The company expects continuing losses and substantial development spending, and may need additional capital. Funding needs and the stated runway depend on assumptions; future financing could dilute shareholders or require restrictions or licensing of valuable rights.
- Since February 2022, the company discontinued or deprioritized three of the five programs it was pursuing at that time. NUV-422 development was discontinued in August 2022 after a safety signal involving uveitis.
- Other key risks include clinical-trial delays or failure, regulatory uncertainty, competition, intellectual-property challenges, reimbursement and drug-pricing pressures, and dependence on key personnel. CEO David Hung holds all Class B shares, which carry significant director-election and transaction approval rights and concentrate voting control.
- No material legal proceedings were reported. A Delaware Court of Chancery order in March 2023 validated the company’s amended certificate of incorporation and shares issued in reliance on it. Management reported effective disclosure controls and internal control over financial reporting as of year-end; the auditor issued an unqualified financial-statement opinion and reported no critical audit matters.
Key facts investors should verify
- Progress, safety findings and dose selection in the ongoing NUV-868 combination studies, and the timing and design of any Phase 2 trial.
- Whether NUV-1511’s planned Phase 1/2 trial began on schedule, and what clinical data show about tolerability and activity.
- Actual cash burn, changes in the $611.2 million liquidity balance, and whether management’s operating runway assumptions remain valid.
- Further program prioritization, trial or manufacturing delays, and any need for financing or partnering that could affect development plans or shareholder dilution.
- The potential impact of CEO voting control, outstanding options and warrants, and future equity-plan share issuance on governance and ownership.